• Myeloma Clinical Trials
    • Feb 03, 2017

    Clinical Trial: Oral Ixazomib Maintenance for Non-Transplant Myeloma Patients

Ixazomib (Ninlaro) is an oral proteasome inhibitor approved in late 2015. It is now being used in a wide variety of treatment combinations and is also being evaluated as maintenance therapy.

For patients who have received prior treatment and achieved some sort of major response (complete response, very good partial response or partial response), investigators are comparing ixazomib maintenance vs. no maintenance. The study will help investigators understand the impact of ixazomib as maintenance therapy and how it impacts progression free survival compared to no maintenance therapy.

The study is open at 6 myeloma academic centers and is only for patients who have NOT undergone a stem cell transplant. To learn more, click the button below:

Ixaxomib Maintenance Trial

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

MYELOMA CROWD RESEARCH INITIATIVE
$49,561 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

Get Started Today.

Find a Clinical Trial that's Right for You

Thanks to our site sponsors: